All In Biotech

Drug Trial Radar · NCT06552234

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Open-label Phase II Efficacy Study of Repotrectinib in Frail (PS ≥2) and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Sep 2031

Study completion Sep 2031

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Groupe Francais De Pneumo-Cancerologie; Hospices Civils de Lyon
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib. However, many patients develop resistance to the tyrosine-kinase inhibitors (TKIs), creating a need for new treatments. Repotrectinib is a new-generation TKI designed against ROS1 or NTRK rearranged malignancies (Drilon 2018). Early phase clinical data support activity of repotrectinib in patients with NSCLC harboring such gene rearrangements (TRIDENT-1 study), but there are limited evidence in frail populations, such as poor performance status patients and/or elderly patients, who are classically excluded from clinical trials or underrepresented. The present study aims to assess the activity and tolerability of repotrectinib in frail (PS ≥2) and/or elderly patients with ROS1-rearranged advanced NSCLC.

Conditions

  • NSCLC Stage IV
  • NSCLC, Stage III

Interventions

  • RepotrectinibDrug

    Repotrectinib 160 mg BID, until progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) according to RECIST v1.1.Time frame: From the date of first treatment administration until the date of disease progression or death if patient died before progression) or the introduction of a new treatment, which ever occurs earlier, assessed up to 7 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France · Recruiting

  • CHU Bordeaux

    Bordeaux, France · Recruiting

  • CHU Brest

    Brest, France · Recruiting

  • Centre François Baclesse

    Caen, France · Recruiting

  • CH Chambéry

    Chambéry, France · Recruiting

  • Hôpitaux civils de Colmar

    Colmar, France · Recruiting

  • CHI Créteil

    Créteil, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • CHRU Lille

    Lille, France · Recruiting

  • CHU Limoges

    Limoges, France · Recruiting

  • Hospices Civils de Lyon

    Lyon, France · Recruiting

  • CH Cornouaille

    Quimper, France · Recruiting

  • CHU Rennes

    Rennes, France · Recruiting

  • CHU Rouen

    Rouen, France · Recruiting

  • Hôpital Foch

    Suresnes, France · Recruiting

  • CHU Toulouse

    Toulouse, France · Recruiting

  • Hôpitaux Nord-Ouest

    Villefranche-sur-Saône, France · Recruiting

  • CH Aix-en-Provence

    Aix-en-Provence, Bouches Du Rhône, France · Recruiting

  • AP-HM

    Marseille, Bouches Du Rhône, France · Recruiting

  • HIA Sainte Anne

    Toulon, Var, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.